# This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En

Source: https://onco.cc/trials/nct07028853/  
OnCo record `nct07028853` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Mevrometostat, Enzalutamide in prostate cancer, run by Pfizer, now recruiting.

## Summary

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. is a phase 3 interventional study registered as NCT07028853 by Pfizer, with 1000 participants planned, started 2025-09-28 and due to reach its primary completion in 2028-09-12. Interventions recorded: Mevrometostat, Placebo, Enzalutamide. Conditions listed: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07028853
- Phase: 3
- Setting: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
- Sponsor: Pfizer
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT07028853: https://clinicaltrials.gov/study/NCT07028853

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Mevrometostat](https://onco.cc/drugs/mevrometostat/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct07028853.json